Serina Therapeutics, Inc. (SER) - Dilution Analysis

S-3 filing: This prospectus relates to the resale of up to 16,450,442 shares of common stock by selling stockholders, consisting of PIPE shares, shares underlying pre-funded and redeemable warrants, and shares underlying convertible preferred stock.

10-Q filing | 15.0M shares outstanding

10-K filing | 12.3M shares outstanding

10-Q filing | 10.3M shares outstanding

10-Q filing | 10.0M shares outstanding

10-Q filing | 9.8M shares outstanding

S-3 filing: This prospectus relates to the resale from time to time by the selling stockholder identified herein of up to 5,593,972 shares of common stock.

8-K filing: Serina Therapeutics, Inc. completed a private placement of securities, issuing 962,250 shares of Series A Convertible Preferred Stock at $5.18 per share, resulting in gross proceeds of approximately $5 million. ($5.0M proceeds)

S-3 filing: This is an S-3 filing related to a potential offering of common stock, where underwriters may purchase and sell shares in the open market, including short sales and stabilizing transactions. Legal matters will be passed upon by Bradley Arant Boult Cummings LLP.

10-K filing | 9.9M shares outstanding

8-K filing: Serina Therapeutics, Inc. sold 500,000 shares of common stock to Juvenescence Limited for $10.00 per share, totaling $5 million, on November 27, 2024, as the first tranche of a larger agreement. Juvenescence also surrendered 755,728 warrants to the company which the company cancelled ($5.0M proceeds)

10-Q filing | 8.9M shares outstanding

10-Q filing | 8.9M shares outstanding

S-1/A filing: This S-1/A filing describes a primary offering of common stock issuable upon exercise of warrants and warrants to purchase common stock, and a secondary offering of common stock issuable upon exercise of warrants and common stock outstanding.

S-1/A filing: Serina Therapeutics, Inc. is filing an S-1/A for a primary offering of up to 3,000,568 shares of common stock issuable upon exercise of warrants and up to 1,500,284 warrants to purchase shares of common stock, as well as a secondary offering of up to 1,889,321 shares of common stock issuable upon exercise of warrants and up to 2,267,188 shares of common stock outstanding.

8-K filing: On June 6, 2024, Juvenescence exercised warrants to purchase 377,865 shares of the Company's Common Stock at an exercise price of $13.20 per share, for a total purchase price of $4,987,818. ($4.99M proceeds)

10-Q filing | 8.4M shares outstanding

S-1 filing: This S-1 filing registers shares of common stock issuable upon the exercise of warrants and shares of common stock held by selling securityholders.

10-K filing | 2.5M shares outstanding

8-K filing: Stock split 1-for-35.17 | Outstanding: 37,951,261 → 1,077,815

8-K filing: AgeX issued 29,388,888 shares of common stock to JuvVentures upon the conversion of Series A and Series B preferred stock.

10-Q filing | 38.0M shares outstanding

10-Q filing | 38.0M shares outstanding

8-K filing: AgeX issued 211,600 shares of Series A Preferred Stock and 148,400 shares of Series B Preferred Stock to Juvenescence in exchange for the cancellation of $36 million of indebtedness. ($36.0M proceeds)

10-Q filing | 38.0M shares outstanding

10-K filing | 37.9M shares outstanding

10-Q filing | 37.9M shares outstanding

10-Q filing | 37.9M shares outstanding

10-Q filing | 37.9M shares outstanding

10-K filing | 37.9M shares outstanding

10-Q filing | 37.9M shares outstanding

10-Q filing | 37.9M shares outstanding

10-Q filing | 37.9M shares outstanding

10-K filing | 37.9M shares outstanding

8-K filing: AgeX's subsidiary LifeMap Sciences, Inc. entered into a Merger Agreement with Atlas Capital Partners Limited and GCLMS Acquisition Corporation, resulting in LifeMap merging with Merger Sub, and AgeX converting $1,761,296.20 of LifeMap's indebtedness into 32,556,306 shares of LifeMap common stock prior to the merger.

S-3/A filing: The filing is an S-3/A form that registers the offer and sale of up to $50.0 million in the aggregate of common stock, preferred stock, warrants, and units, as well as the offer and resale of up to an aggregate of 19,695,746 shares of common stock by the selling security holder, and $12,600,000 of common stock offered through Chardan Capital Markets LLC.

S-3 filing: AgeX is offering common stock, preferred stock, warrants and units up to $50 million. Additionally, a selling security holder is offering 19,366,799 shares of common stock for resale. AgeX is also offering shares of common stock up to $12,600,000 in an at-the-market offering through Chardan Capital Markets LLC.

10-Q filing | 37.7M shares outstanding

10-Q filing | 37.7M shares outstanding

10-Q filing | 37.7M shares outstanding